Navigation Links
Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
Date:10/2/2011

's lead product candidate, is an intravenous recombinant FIX product being developed for the treatment and prevention of bleeding in individuals with hemophilia B.  IB1001 has completed the pivotal Phase 3 clinical testing for the European regulatory submission, while clinical testing for the U.S. regulatory submission is ongoing.  To date, IB1001 has been well-tolerated by patients and pharmacokinetic results have demonstrated non-inferiority to the one approved recombinant FIX product currently available for the treatment of hemophilia B.

About Inspiration BiopharmaceuticalsInspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and to improve the treatment of individuals with inhibitor complications.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two pre-clinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product for the treatment of individuals with congenital hemophilia A who have developed inhibitors against human FVIII and for individuals with acquired hemophilia.  Both products are in advanced clinical development.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration has extensive expertise and experience in hemophilia product development, biologics manufacturing, regulatory approval and global commercialization. The Company's
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
5. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
9. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
11. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... York, NY (PRWEB) September 18, 2014 ... completed negotiations with Salem Realty Group and has acquired ... development space within the Salem Executive Complex adjacent to ... ceremony was held on Friday September 5th. Whitehouse Labs ... refit the entire space specifically for package testing. The ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... protected regenerative biomaterials and bioimplants processed from human ... clinical study.    The study article, ... Trial Evaluating the Use of Dehydrated ... Therapy vs. Multi-layer Compression Therapy Alone in the ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... Health Care Compliance Strategies, Inc. (HCCS) announced today ... and man-made disasters, it will extend free unlimited ... and Disaster Preparation" for an additional year.  ... "HCCS CARES" allows any healthcare administrator or ...
... 8, 2012  Ekahau Inc., the ... (RTLS), today announced the launch of its newest Wi-Fi staff ...  The B4 features an OLED text display and multiple buttons that ... receipt or to initiate calls and alarms. A unique feature of ...
... Inc. (Nasdaq: SGMO ) announced today that Edward ... the progress of Sangamo,s ZFP Therapeutic® development programs and an ... , The 11th Annual JMP Securities Research Conference ... ET), on Monday, May 14, 2012. , The Bank ...
Cached Biology Technology:Free Disaster Preparedness Online Training Course 2Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager 2Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager 3Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences 2
(Date:9/17/2014)... disposable plastic shopping bags and their environmental impact recently ... the first statewide ban on the bags, and Governor ... plastic bag industry is not yielding without a fight, ... News , the weekly newsmagazine of the American Chemical ... reports that the anti-bag campaign logged its first small ...
(Date:9/17/2014)... (Hospital del Mar Medical Research Institute) and at the ... study in eLife showing that RNA called ... of new proteins, some of which could have important ... from the instructions found in an RNA molecule. However, ... information for the synthesis of proteins, meaning it is ...
(Date:9/17/2014)... Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by David ... normal accompanying cells in colorectal tumors. Analysis of ... tumors, predict the evolution of the patient and ... , Biomarkers , Colorectal cancer ... both sexes. About 30,000 new cases are diagnosed ...
Breaking Biology News(10 mins):Parts of genome without a known function may play a key role in the birth of new proteins 2Five genes to predict colorectal cancer relapses 2
... WASHINGTON Synthetic biology promises to enable cheap, lifesaving ... suffer from malaria, and to create innovative biofuels that ... the science and its applications are raising questions: ... purposely changing the definition of what is life? ...
... Carolina, there are five strange looking "patches" cleared out ... circles carved by aliens. , They,re actually budding longleaf ... St. Louis and their collaborators at North Carolina State ... Washington have created these ecological patches with the help ...
... French . Plant researchers from ... announced a major breakthrough in a developmental process called ... reversal of what is called epigenetic silencing in plants. ... better understanding of gene regulation in the continuing quest ...
Cached Biology News:Synthetic biology: Is ethics a showstopper? 2Study on wildlife corridors shows how they work over time 2Study on wildlife corridors shows how they work over time 3Study on wildlife corridors shows how they work over time 4Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3
... Rabbit polyclonal to Kv4.2 Immunogen ... KLH, corresponding to amino acids 23-43 of ... Cross-reacts with Rat.Expected to cross-react with Human ... with immunogen), Rabbit (100% identity with immunogen) ...
... 2 Alzheimer's disease (AD) patients with ... mutations in the presenilin proteins (PSEN1; PSEN2) ... disease-linked mutations result in increased production of ... of amyloid deposits found in AD brains). ...
See product name for description....
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Biology Products: